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Objective: Non-coding RNAs constitute a major fraction of the b-cell transcriptome. While the involvement of microRNAs is well established, the
contribution of long non-coding RNAs (lncRNAs) in the regulation of b-cell functions and in diabetes development remains poorly understood. The
aim of this study was to identify novel islet lncRNAs differently expressed in type 2 diabetes models and to investigate their role in b-cell failure
and in the development of the disease.
Methods: Novel transcripts dysregulated in the islets of diet-induced obese mice were identiﬁed by high throughput RNA-sequencing coupled
with de novo annotation. Changes in the level of the lncRNAs were assessed by real-time PCR. The functional role of the selected lncRNAs was
determined by modifying their expression in MIN6 cells and primary islet cells.
Results: We identiﬁed about 1500 novel lncRNAs, a number of which were differentially expressed in obese mice. The expression of two lncRNAs
highly enriched in b-cells, blinc2, and blinc3, correlated to body weight gain and glycemia levels in obese mice and was also modiﬁed in diabetic db/
dbmice. The expression of both lncRNAswas alsomodulated in vitro in isolated islet cells by glucolipotoxic conditions. Moreover, the expression of the
human orthologue of blinc3was altered in the islets of type 2 diabetic patients and was associated to the BMI of the donors. Modulation of the level of
blinc2 and blinc3 by overexpression or downregulation in MIN6 and mouse islet cells did not affect insulin secretion but increased b-cell apoptosis.
Conclusions: Taken together, the data show that lncRNAs are modulated in a model of obesity-associated type 2 diabetes and that variations in
the expression of some of them may contribute to b-cell failure during the development of the disease.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Type 2 diabetes (T2D) is characterized by reduced insulin action and/or
insulin deﬁciency [1,2]. Insulin is responsible for the control of blood
glucose levels and its release is ﬁnely tuned by nutrients, hormones,
and neurotransmitters. Under obese conditions, a major risk factor for
T2D, the peripheral tissues become less sensitive to insulin [3]. To
maintain euglycemia and overcome peripheral insulin resistance, b-
cells expand and increase their secretory activity [3]. However, in
genetically predisposed individuals, defects in this process can lead to
progressive deterioration of b-cell function and loss of b-cell by
apoptosis, promoting the development of diabetes [3e5].
The mechanisms underlying compensatory b-cell mass expansion, b-
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oxidative and endoplasmic reticulum stress, dysfunctional triglyceride/
free fatty acid cycling, and glucolipotoxicity [3,5]. These phenomena
trigger alterations in the level of key protein-coding genes and
microRNAs [3,6,7], a class of small non-coding RNAs playing central
roles in numerous physiological and pathological processes [8]. Beside
protein-coding genes and microRNAs, transcriptome analysis identi-
ﬁed another large class of non-coding RNAs, the long non-coding RNAs
(lncRNAs) [9e12]. These non-coding transcripts participate in diverse
gene-regulatory mechanisms [13e15] and their dysregulation has
been implicated in many human diseases [16]. Recently, lncRNAs were
found to contribute to b-cell development and glucose homeostasis
[17,18] and to be involved in b-cell demise during the initial phases of
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Original Articlebeen functionally characterized and very little is known about their
possible contribution to T2D development.
The aim of this study was to identify novel islet lncRNAs and to
investigate their role in the regulation of b-cell functions. The
expression of lncRNAs is highly cell-type and context speciﬁc. In view
of this, we used RNA-sequencing to explore unbiasedly the islet
transcriptome for novel lncRNAs expressed in mice fed a high-fat diet,
a model of mild diabetes associated with obesity that corresponds to
early diabetes in human [21]. We identiﬁed several not yet annotated
lncRNAs, a number of which displayed expression changes between
islets of lean and obese mice. Analogous changes of selected lncRNAs
were also observed in islets of obese diabetic db/db mice and in the
islets of T2D donors. In addition, the modulation of some of these
lncRNAs in dissociated mouse islet cells sensitised the b-cells to
apoptosis. Overall, the results show that lncRNAs are modulated in
islets from obese diabetic mice and T2D individuals and may
contribute to b-cell failure during T2D development.
2. MATERIAL AND METHODS
2.1. Chemicals
IL-1b, leptomycin B, collagenase, and Histopaque were purchased
from SigmaeAldrich (St Louis, MO, USA), TNF-a from Enzo Life sci-
ences (Farmingdale, NY, USA) and IFN-g from R&D systems (Minne-
apolis, MN, USA).
2.2. Animals
Five-week old male C57BL/6 mice (Charles River Laboratories,
Raleigh, NC, USA) were fed a normal (ND) or a high-fat diet (HFD) for 8
weeks (Bioserv F-3282, 60% energy from fat, Frenchtown, NJ, USA)
[21]. The animals on high fed diet were subdivided in low (LDR) and
high responders (HDR) according to the criteria deﬁned in Peyot et al.,
2010 [21]. The mice in the LDR group weighted between 33 and 39 g
after 7.5 weeks on HFD while the animals in the HDR group between
39 and 45 g. C57BL/KsJ db/dbmice (13e16 weeks) and age-matched
lean db/þ littermates were obtained from the Garvan Institute breeding
colonies (Sydney, NSW, Australia) [22]. Mice expressing the enhanced
yellow ﬂorescence protein in b-cells (RIPYY) were obtained by crossing
rosa-26EYFP with RIP-Cre mice [23]. Animal procedures were per-
formed in accordance with National Institutes of Health guidelines and
were approved by research councils and veterinary ofﬁces.
2.3. Islet and insulin-secreting cells
Mice islets were isolated by collagenase digestion followed by Histo-
paque density gradient [24] and cultured in RPMI medium [19]. Islets
from RIPYY mice were either directly used to isolate the RNA or
dissociated to separate b- from non-b cells by FAC-sorting [23]. Hu-
man islets were provided by the Cell Isolation and Transplantation
Center (University of Geneva) or by the Human Tissue Lab of EXODIAB/
Lund University Diabetes Centre through the Nordic Network for Islet
Transplantation, Uppsala University. After isolation, the human islets
were utilized for RNA isolation or cultured in CMRL medium (Invitrogen)
supplemented with 10% FCS, 100 mg/mL streptomycin and 100 IU/mL
penicillin (Invitrogen), 2 mmol/L L-glutamine and 250 mmol/L HEPES.
Dissociation of mice and human islets was achieved by incubation at
37 C in PBS containing 3 mM EGTA and 0.002% trypsin. MIN6B1 cells
were cultured in DMEM-Glutamax medium (Invitrogen) [25].
2.4. RNA-sequencing and analysis
RNA was isolated using the RNeasy kit (Qiagen), followed by DNase
treatment (Promega). Ribosomal RNA was removed using the Ribo-1408 MOLECULAR METABOLISM 6 (2017) 1407e1418  2017The Authors. Published by Elsevier GmbH.Zero Magnetic Gold kit (MRZG126, Illumina), and sequence libraries
were prepared using the Illumina TruSeq stranded mRNA LT kit without
poly(A) selection in order to include also all the lncRNA transcripts that
are not polyadenylated. Libraries were sequenced with the Illumina
HiSeq2000. 100nt paired-end reads from 6 samples were mapped to
mm9 reference genome using Tophat software version 2.0.8 [26] with
the option ”Gene model” eG, using mm9 UCSC reference genes GTF
[27]. Ab initio transcript reconstruction was performed using Cufﬂinks,
version 2.1.1 [26], with option eG and the reference UCSC genome.
The resulting GTFs were merged using Cuffmerge v2.1.1 [28] to
distinguish known and novel transcripts. Using the output of Cuff-
merge, the transcripts were divided into 3 categories: known mRNAs,
known lncRNAs (UCSC as reference), and novel lncRNAs. Novel tran-
scripts were ﬁltered for having at least 2 exons. Read counts were then
calculated per gene from the alignment bam ﬁles using HTSeq
(v0.5.4p3) with options em union estranded no. Genes were then
ﬁltered for minimal expression (mean counts5 across all conditions).
The protein-coding potential of transcripts was evaluated using the
program GeneID [29], v1.4.4, applied to transcript sequences in FASTA
format, with parameters adapted for vertebrates as provided by the
authors in ﬁle GeneID.human.070123.param and with options es and
eG. Transcripts with a coding potential >4 were removed from the
analysis. Differentially expressed genes were detected using the limma
package in R by ﬁrst transforming the raw count data to log2 counts
per million reads using the voom function. Empirical Bayes moderated t
statistics and corresponding p-values were computed for the com-
parison and p-values adjusted for multiple comparisons using the
Benjamini-Hochberg procedure [30]. Genes with an adjusted p-value
of 0.05 were considered differentially expressed. Differential anal-
ysis by transcripts was done using Cuffdiff, v2.1.1 [28], on a gtf ﬁle
containing the coordinates of the novel transcripts. Gene ontology
analysis was performed by submitting the genes lists to the DAVID
Functional annotation clustering tool using default parameters (https://
david.ncifcrf.gov/tools.jsp).
2.5. Measurement of lncRNAs expression
RNA was reverse transcribed using M-MLV reverse transcriptase,
RNAse H minus (Promega). Quantitative PCR was performed using iQ
SYBR Green mix and samples were ampliﬁed using the CFX Connect
Real-time system (Bio-Rad). Islets of human control and T2D patients
were homogenized by vortexing in 700 uL Qiazol lysis buffer and the
RNA extracted using the miRNeasy kit (Qiagen) with DNase treatment.
100ng total RNA was used for reverse transcription using the High
Capacity cDNA kit with RNAse inhibitor (ThermoFisher). For qPCR,
PowerUP SYBR Green Master Mix (Applied Biosystems) was used with
assay-speciﬁc primers (Supplemental Table 1).
2.6. Subcellular fraction
MIN6B1 cells were incubated for 15 min in ice-cold lysis buffer (10 mM
TriseHCl, pH 7.5, 0.05% NP40, 3 mM MgCl2, 10 mM NaCl and 5 mM
EGTA) and then centrifuged 10 min at 2,000 g. The supernatant
(cytoplasmic fraction) was recovered while the pellet was resuspended
in 10 mM HEPES, pH 6.8, 300 mM sucrose, 3 mM MgCl2, 25 mM NaCl,
1 mM EGTA, 0.5% Triton-X-100 and treated with 700 U/ml DNAse I for
30 min at 4 C. The samples were then centrifuged at 17,000 g for
20 min and the pellet collected as nucleoplasmic fraction.
2.7. Transfection
Overexpression of lncRNAs was achieved by transfecting pcDNA3-
based plasmids with Lipofectamine 2000 (MIN6B1 cells) or 3000
(primary cells) (Invitrogen). Down-regulation was carried out byThis is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
transfecting Gapmers (Exiqon) with RNAiMax (Invitrogen) (gapmers
sequences in Supplemental Table 1).
2.8. Insulin secretion
Insulin secretion of MIN6B1 cells was carried out as described [25].
2.9. Assessment of cell death
Apoptotic cells displaying pyknotic nuclei were scored under blind
conditions by ﬂuorescence microscopy (AxioCam MRc5, Zeiss, Feld-
bach, Switzerland) after incubation with 1 mg/ml Hoechst [25] or
TUNEL assay (Roche).
2.10. NF-kB nuclear translocation
MIN6B1 cells were transfected with a plasmid expressing a GFP-
tagged form of NF-kB subunit p65 (Rela) and/or the plasmid
expressing the lncRNA. 24 h later, the cells were treated with the
indicated compounds for 3 h, ﬁxed, and mounted on a coverslip for
microscopic examination.
2.11. Statistical analysis
Data are presented as mean  sem. Statistical differences were
assessed by two-tailed paired Student’s t-test when only two sets of
data were present or by one-way ANOVA with more than 2 groups with
a discriminating p-value of 0.05 (GraphPad Prism). Correlations be-
tween lncRNA expression and different characteristics of the in-
dividuals were performed by linear regression, where F-test was used
to determine signiﬁcance at p < 0.05.
ACCESION NUMBERS: RNA-sequencing data have been deposited in
the Gene Expression Omnibus Database, accession number
GSE92602.
3. RESULTS
To investigate the contribution of lncRNAs to b-cell dysfunction and
T2D development, we compared the transcriptome of islets from mice
fed a regular and a high-fat diet. The metabolic characteristics of these
animals are summarized in Supplemental Table 2. RNA-sequencing
yielded w500.000.000 reads per sample (accession number
GSE92602), of which,w75% were mapped to the mouse genome. Ab
initio transcript assembly was performed using Cufﬂinks [26], and
novel transcripts were classiﬁed from known lncRNAs and protein-
coding mRNAs. Hierarchical clustering showed a distinguishable
expression proﬁle between the two groups (Figure 1A). The analysis
detected 14874 protein-coding genes, of which, 971 were upregulated
and 395 downregulated in mice fed a high-fat diet (Figure 1B and
Supplemental Table 3). Functional annotation of the differentially
expressed protein-coding genes showed enrichment for biological
pathways related to protein localization and transport, redox pro-
cesses, intracellular transport (Supplemental Fig. 1). Of these differ-
entially expressed genes, 21.2% overlapped with those previously
identiﬁed by microarray [31]. We also detected 1761 UCSC annotated
lncRNAs (23 upregulated and 104 downregulated) and 1996 non-
annotated UCSC lncRNA genes (4303 transcripts), of which, 39 were
upregulated and 107 downregulated (Figure 1B, Supplemental
Tables 4 and 5). Amongst the non-annotated lncRNAs, 438 over-
lapped with recently published transcripts [32,33] while 1558 were
novel. We compared our mouse data with those of Moran et al. [34]
obtained in human using TransMap, a cross species mRNA align-
ment tool. A list of mouse lncRNA genes for which we were able to
identify the corresponding human orthologues is provided in the
Supplemental Table 6. The GeneID-coding potential score revealedMOLECULAR METABOLISM 6 (2017) 1407e1418  2017TheAuthors. Published by ElsevierGmbH. This is an o
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tential (Figure 1C). The expression level of the novel lncRNAs over-
lapped that of UCSC-annotated lncRNAs and was usually lower than
that of protein-coding genes (Figure 1D). The coordinates of all newly
annotated transcripts is available on GEO (accession number
GSE92602).
We then used different criteria to select candidate lncRNAs for further
analysis, including clearly detectable expression changes in response
to high-fat diet, the presence of a small number of isoforms to avoid
dealing with several overlapping transcripts with potentially different
functions, and the putative presence of human orthologues. Multidi-
mensional analysis revealed that the transcriptome of one of the an-
imals (HDR3) was slightly different from the other mice on high-fat diet
(Supplemental Fig.2). To avoid missing potentially interesting candi-
dates, we included in our initial screening also the lncRNAs showing
signiﬁcant differences between control mice and the other two mice on
HFD (Supplemental Table 7). We selected two intergenic lncRNAs
(XLOC_010971 and XLOC_013310) for further analysis. The chro-
mosomal location and the fold changes of these two novel lncRNAs are
shown in Figure 1B. Since there is not yet a consensus for the
nomenclature of mouse lncRNAs, they are hereafter referred to as
blinc2 and blinc3 (b long intergenic noncoding RNA 2 and 3) to follow
Arnes et al. nomenclature [18]. The locus architecture, the number of
isoforms, and the coding potential of blinc2 and blinc3 are provided in
Figure 1EeF and in the Supplemental Table 8. Subcellular fraction-
ation of MIN6B1 cells revealed that blinc2 is present both in the
cytosolic and in the nuclear fractions while blinc3 is essentially nuclear
(Supplemental Fig. 3).
The changes observed by RNA-sequencing were conﬁrmed by qRT-
PCR in additional samples of high responders to the high-fat diet
(HDR), as well as in low responders (LDR), a group of animals dis-
playing the phenotypic characteristic of pre-diabetes when compared
to obese humans [21]. The level of blinc2 was not increased in the LDR
group with no glycemic alterations but was upregulated 49 times in the
HDR group that shows mild hyperglycemia [31]. The expression of
blinc3 tended to decrease already in the LDR group but reached
signiﬁcance only in the HDR group that displayed 60% lower levels
compared to controls (Figure 2AeB). The expression of these tran-
scripts was also analyzed in the islets of db/db mice, which lack the
leptin receptor and develop severe obesity associated with T2D
[22,35]. The increase of blinc2 was more pronounced than in HDR
mice, with an up-regulation of 1802-fold, whereas the decrease in
blinc3 expression was similar to that observed in response to high-fat
diet HDR group (Figure 2CeD).
We then tested whether the expression of these two lncRNAs corre-
lated with body weight, glycemia, and insulinemia of animals fed
normal and high-fat diets (metabolic characteristics are provided in
Supplemental Table 9). As shown in Figure 3 A, C, E we found a
positive correlation between the level of blinc2 with body weight,
glycemia, and insulinemia. This was true even when performing the
analysis after the exclusion of the highest point (Supplemental Fig. 4).
The raise of blinc2 was mainly observed in animals weighing >40 g,
suggesting the existence of a threshold. In contrast, the expression of
blinc3 was negatively correlated with these parameters except for
insulinemia (Figure 3B,D,F).
To assess whether the expression of these two novel lncRNAs is
restricted to pancreatic islets, we analyzed their levels in a large panel
of tissues. We found that blinc2 is undetectable in the investigated
tissues except in heart, where the expression is about 100 times lower
compared to islets (Figure 4A). blinc3 was only detectable in heart and
brain, but again at much lower levels compared to islets (Figure 4B). Topen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1409
Figure 1: Overview of the RNA-sequencing results. A. Hierarchical clustering of samples using the 500 genes displaying the highest mean expression. Colors display Euclidian
distance, red represents no distance, yellow means there is a longer distance. ND, normal diet; HDR, high-(high fat diet) responders. B. Summary of differentially expressed genes
(up right) and studied lncRNAs with fold changes and p-values (bottom right). C. Coding potential for novel transcripts compared to known coding genes. The red line represents the
cutoff used to ﬁlter and classify the novel transcripts (<4, GeneID). D. Size distribution of protein-coding genes, known and novel lncRNAs. E. Locus architecture and isoforms of
the blinc2 gene. F. Locus architecture and isoforms of the blinc3 gene.
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Figure 2: The expression levels of two lncRNAs are modiﬁed in islets from mice fed a high fat diet and in db/db mice. Expression of blinc2 and blinc3 in C57BL/6 mice fed a
normal diet (ND) and in low-(high fat diet) responders (LDR) and in high-(high fat diet) responders (HDR) (A,B) and from db/þ, db/db mice (C,D). Islets were isolated from mice of 14
weeks of age after being fed a standard or a high fat diet for 8 weeks and from db/db mice of 13e16 weeks of age. The expression levels of the lncRNAs were measured by real-
time PCR and normalized to Gapdh. t-test or ANOVA, KruskaleWallis post hoc test, *P < 0.05 **P < 0.01, ***p < 0.001 vs ND or db/þ.assess whether these lncRNAs are expressed in insulin-secreting cells,
we measured their level in highly puriﬁed (w99%) b-cell fractions
obtained from FAC-sorted islet cells [23]. We found that blinc2 and
blinc3 are indeed abundant in the b-cell fraction (Figure 4CeD).
To determine the possible causes of the changes in lncRNA expression
detected in the islets of obese mice, we exposed normal mouse islets
to pathophysiological concentrations of glucose and palmitate. The
expression of blinc2 increased in the presence of high glucose
(20 mM) and palmitate (0.5 mM), whereas blinc3 was only modiﬁed by
the presence of palmitate (Figure 5). These changes were not observed
upon incubation of dissociated islet cells with pro-inﬂammatory
cytokines (Supplemental Fig. 5).
Subsequently, we searched for human orthologues of these two
lncRNAs. We mapped the identiﬁed mouse lncRNA sequences to the
human genome using TransMap. To validate the predicted orthologues
we designed primers in the putative exons. This enabled us to detect
the orthologue for blinc3 (region shown in Supplemental Table 10) but
not for blinc2. As was the case for its mouse orthologue, the
expression of human bLINC3 was not modiﬁed in the presence of
20 mM glucose but was decreased about 30% upon incubation with
0.5 mM palmitate (Figure 6).
In view of these ﬁndings, we assessed whether the expression of
human bLINC3 is diminished in the islets of T2D patients. The char-
acteristics of the non-diabetic and diabetic donors are summarized in
Figure 7A. Human bLINC3 expression was 75% lower in donors with
T2D than in controls (Figure 7B). Furthermore, as was the case in mice,
there was a negative correlation between the level of this lncRNA and
the BMI of the subjects (Figure 7C). We also observed a trend for a
negative correlation between the expression of human bLINC3 and
HbA1c, but the values did not reach statistical signiﬁcance (Figure 7D).
There was no correlation with the age of the donors (data not shown).
To assess the possible contribution of blinc2 and blinc3 to the regu-
lation of speciﬁc b-cell functions, we modiﬁed their level in MIN6 andMOLECULAR METABOLISM 6 (2017) 1407e1418  2017TheAuthors. Published by ElsevierGmbH. This is an o
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blinc3 in MIN6 cells (Supplemental Fig. 6) did not modify proinsulin
mRNA levels, insulin content, or insulin release (Supplemental Fig. 7).
As an increase in b-cell apoptosis and a consequent reduction in the
b-cell mass can contribute to T2D development [4], we investigated
the impact of changes in the expression of these lncRNAs on b-cell
survival. We observed that the up-regulation of blinc2 increases
apoptosis of both MIN6 (Figure 8A) and dissociated mice islet cells
(Figure 8C) to a level similar to the one seen upon 24 h exposure to
pro-inﬂammatory cytokines (used as a positive control for apoptosis).
Overexpression of blinc3 did not affect cell survival (Figure 8AeC).
However, downregulation of blinc3 in MIN6 and dissociated mice islet
cells, mimicking the conditions encountered under diabetic state,
resulted in a rise in the number of apoptotic cells (Figure 8CeD).
Similar results were obtained by TUNEL assay and using a different
gapmer targeting blinc3 (Supplemental Fig. 8 and 9).
Increasing evidence suggests an involvement of inﬂammatory pro-
cesses in the pathogenesis of T2D and activation of the NF-kB
pathway has been implicated in glucolipotoxic-induced b-cell
apoptosis [36e38]. Among other mediators, hyperglycemia and
hyperlipidemia increase the production and the release of IL-1b, a pro-
inﬂammatory cytokine that activates the transcription factor NF-kB and
that has been widely studied in the context of type 1 diabetes [39].
Since one of the initial events occurring shortly after b-cell exposure to
IL-1b is the translocation of NF-kB to the nucleus [40], we transfected
MIN6 cells with a GFP-tagged form of p65 (the main NF-kB subunit)
[39,41] and monitored its subcellular distribution after modulating the
level of the lncRNAs. We found that incubation of the cells with lep-
tomycin B, a compound that impedes the nuclear exit of NF-kB [42]
was sufﬁcient to increase the fraction of cells in which p65 was
localized in the nucleus (Figure 8E). As expected, the localization of
p65 in the nucleus was further increased when incubating the cells
with high concentrations of IL-1b. No difference was seen bypen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1411
Figure 3: Correlations of the expression of blinc2 and blinc3 with body weight, insulinemia, and glycemia of C57BL/6 mice fed a normal or a high fat diet. Linear regression
analysis of the expression of blinc2 versus body weight (A), glycemia (C) and insulinemia (E). Linear regression analysis of the expression of blinc3 versus body weight (B),
glycemia (D) and insulinemia (F). Body weight, Insulinemia and Glycemia were measured at sacriﬁce. Fed blood glucose in HDR and ND mice was measured by a portable
glucometer (Accucheck, Roche). Plasma insulin was measured by ELISA (ultrasensitive mouse insulin kit, ALPCO). The expression levels of the lncRNAs were measured by real-
time PCR and normalized to Gapdh. F-test was used to determine signiﬁcance at p < 0.05.
Original Articleoverexpressing blinc2 alone, but, in the presence of leptomycin B, we
observed an increase in the number of cells in which p65 is localized in
the nucleus similar to the one seen in the presence of IL-1b (Figure 8
and Supplemental Fig. 10). These data suggest that at least part of the
effect of blinc2 on b-cell survival may be related to an increased
shuttling of NF-kB to the nucleus. No differences were seen when up-
regulating (Supplemental Fig. 11) or down-regulating blinc3 (data not
shown). We then assessed whether the changes in the level of blinc2
or blinc3 are directly affecting the expression of key apoptotic genes.
As shown in Supplemental Fig. 12, none of the tested mRNAs was
modiﬁed upon overexpression of blinc2 or down-regulation of blinc3.
4. DISCUSSION
Human islets have recently been shown to express a large number of
lncRNAs that, in concert with transcription factors, regulate the tran-
scriptional landscape of b-cells [34,43]. In this study, we used high-
throughput RNA-sequencing to identify novel lncRNAs modiﬁed in a
mouse model of diet-induced obesity and hyperglycemia that are
potentially involved in the control of b-cell functions and b-cell failure.1412 MOLECULAR METABOLISM 6 (2017) 1407e1418  2017The Authors. Published by Elsevier GmbH.This T2D model integrates both genetic and environmental risk factors.
Amongst the mice fed a HFD, the high responders (HDR) were chosen
for the initial analysis since they correspond to the early diabetes
situations in humans and display phenotypic features such as insulin
resistance, hyperinsulinemia and hyperglycemia [21], typically
encountered during the development of T2D.
The capacity to identify new transcripts is strongly inﬂuenced by the
length and the depth of the sequencing and is more efﬁcient if the
sequencing is paired-ended. Our transcriptomic analysis was carried
out with an unprecedented depth (100 nucleotide paired-end
sequencing and 500 million reads per sample) and included also
RNAs lacking a polyA tail. For comparison, in the other two main
studies devoted to the identiﬁcation of novel lncRNAs in mouse b-cells,
Benner et al. [32] generated 30 million single reads per sample and Ku
et al. [33] 150e371 million 82e85 paired-end sequencing reads per
sample, resulting in the identiﬁcation of 127 and 1359 non-annotated
lncRNAs, respectively. Our comprehensive analysis led to the discovery
of many novel transcripts with minimal protein-coding potential. This is
in line with the view that lncRNA expression is more cell- and context-
speciﬁc compared to that of protein-coding genes [11]. In agreementThis is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: blinc2 and blinc3 are expressed in b-cells and their expression is higher in pancreatic islets compared to other tissues. A) Expression of blinc2 and B) of blinc3 in
pancreatic islets and in different other tissues of C57BL/6 mice at 13 weeks of age. C) Expression of blinc2 and D) of blinc3 in whole islets and in FAC-sorted cells isolated from
RIPYY mice. The expression levels were measured by real-time PCR and were normalized to the level detected in islets. T-test or ANOVA, Tukey post-hoc test. *P < 0.05
**P < 0.01 vs control (whole islets).with other reports [11,34], the level of the newly annotated islet
lncRNAs was lower than that of protein-coding genes and overlapped
that of previously annotated lncRNAs. We found that the expression of
many of the newly annotated lncRNAs is modulated by the diet. We
focused on two lncRNAs that are highly enriched in b-cells compared
to other tissues. We found that the expression of these lncRNAs is
altered also in 13e16 week-old diabetic db/db mice. The down-
regulation of blinc3 was similar in both models, whereas the
expression of blinc2 was more drastically affected in the islets of db/db
mice than in HDR samples. This difference is associated with a more
severe phenotype of b-cell failure and diabetes displayed in db/db
mice compared to high-fat-fed mice [35].
The expression of blinc2 was also positively correlated to body weight,
glycemia, and insulinemia in ND and a HFD mice. However, its level
was not signiﬁcantly increased in the islets of low diet responder mice
(LDR), suggesting that the changes may only occur under severe
obesity and insulin resistant conditions with associated hyperglycemia.
blinc3 expression was negatively correlated to body weight and gly-
cemia but not to insulinemia, suggesting that the decrease of this
lncRNA is mainly associated with the development of obesity and less
with the control of insulin release.
During the development of obesity-associated T2D, b-cells are
chronically exposed to glucolipotoxic conditions [44]. Hence, we
treated mouse islets with increasing concentrations of glucose or with
the free fatty acid palmitate to investigate whether theseMOLECULAR METABOLISM 6 (2017) 1407e1418  2017TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.compathophysiological conditions may explain the changes in lncRNA
expression. Indeed, the level of blinc2 was increased by both elevated
glucose and palmitate concentrations, whereas blinc3 was down-
regulated by palmitate but not by glucose.
LncRNAs are less conserved than protein-coding genes [11] and may
have implications in species-speciﬁc functions [45]. To conﬁrm the
relevance of our ﬁndings for human diabetes we search for potential
orthologues. Unfortunately, although alignment tools indicated the
existence of potential candidate regions, we could not formally identify
a human orthologue of blinc2. The function of lncRNAs can be pre-
served with sequence homologies as low as 21% [46]. Thus,
computational tools based solely on sequence alignments may be
inappropriate for the identiﬁcation of lncRNA orthologues. In the future,
a better understanding of the mode of action of lncRNAs will hopefully
promote the design of new tools to search for orthologues facilitating
the identiﬁcation of human transcripts with functions analogous to
mouse blinc2. Using the available tools, we were able to identify the
orthologue of blinc3 in human islets and to conﬁrm that its levels are
also diminished upon treatment in the presence of elevated concen-
trations of palmitate. Since exposure of islet cells to elevated palmitate
in vitro induces more rapid and harmful effects than those that may
occur in vivo, we measured the level of the human bLINC3 in islets of
control and T2D donors. Interestingly, the level of bLINC3 was lower in
subjects with T2D, and, as was the case in mice, there was a negative
correlation between its expression and the BMI of the subjects.pen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1413
Figure 6: Effects of chronically-elevated glucose and palmitate on the levels of bLINC3 in human islets. Human islets were incubated for 48 h at 5.5, 10 or 20 mM glucose, and at
5.5 mM glucose with and without 0.5 mM palmitate (CMRL, 5% FCS, 0.5% BSA, 5.5 mM glucose). LncRNA expression was measured by real-time PCR and normalized to GAPDH.
Means  SEM of 3 different experiments. *P < 0.05 vs control, either glucose 5.5 mM or no palmitate.
Figure 5: In vitro effects of chronically-elevated glucose and palmitate on the level of two lncRNAs differentially expressed in islets from mice fed a high fat diet. Isolated islets from
C57BL/6 mice fed a regular chow diet were incubated for 48 h at 6, 11 or 20 mM glucose and at 6 mM glucose with or without 0.5 mM palmitate (RPMI supplemented with 5%
FCS, 0.5% BSA and 11 mM glucose). LncRNA expression was measured by real-time PCR and normalized to Gapdh. Means  SEM of 3e4 different experiments. t-test or ANOVA,
Tukey post-hoc test, *P < 0.05 vs control, either glucose 6 mM or no palmitate.
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Figure 7: bLINC3 expression is decreased in islets from type 2 diabetes donors versus controls and inversely correlates to the BMI of the subjects. A. donor characteristics.
B. LncRNA expression between control subjects and type 2 diabetes patients. LncRNA expression was measured by real-time PCR and normalized using three endogenous
controls, 18s rRNA, CYCLOPHILINA and B2M. One tail t-test, *P < 0.05. Linear regression analysis of the expression of human bLINC3 versus BMI (C) and HbA1c (D). F-test was
used to determine signiﬁcance at p < 0.05.Moreover, there was a trend for a negative correlation between the
levels of bLINC3 and HbA1c, suggesting that lower amounts of bLINC3
may result in poorer glycemic control. The analysis of more subjects
would be needed to conﬁrm this assumption.
In genetically predisposed individuals, the progression of the disease
coincides with a gradual deterioration in b-cell functions, in part
associated with the loss of b-cells by apoptosis [3,5]. The modulation
of these two lncRNAs had no impact on insulin biosynthesis or release,
but the increase of blinc2 and the decrease of blinc3 resulted in a rise
in the number of apoptotic cells. Thus, altered expression of these
lncRNAs cannot explain the secretory defects observed in db/db or HFD
mice but may contribute to b-cell failure during the development and
the progression of the disease.
The precise mechanisms underlying the effect of blinc2 and blinc3 on
b-cell apoptosis remains to be determined. We found that over-
expression of blinc2, increases the rate of NF-kB nuclear trans-
location. Although basal NF-kB activity is required for normal insulin
release [47], its prolonged activation plays a central role in cytokine-
and in glucolipotoxic-induced b-cells death [37,40]. One of the initial
events leading to the activation of NF-kB, for instance in response to
IL-1b [40], a cytokine produced in conditions of hyperglycemia and
hyperlipidemia [48,49], is its translocation to the nucleus. Since the
extent of the induction of NF-kB target genes is inﬂuenced by different
events including the speed of the nuclear translocation of the tran-
scription factor and/or a more sustained activation of this pathway
[39,40], it is possible that an increased shuttling of NF-kB to the
nucleus may promote the activation of this signaling cascade ulti-
mately contributing to apoptosis. Despite the increased shuttling of
p65 to the nucleus, we did not detect signiﬁcant changes in the mRNA
level of key apoptotic genes. This may be due to the fact that the
fraction of cells in which the transcription factor is moving to the
nucleus is too small to result in changes in gene expression detectable
in the whole cell population. Alternatively, the translocation of p65 toMOLECULAR METABOLISM 6 (2017) 1407e1418  2017TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.comthe nucleus alone may not be sufﬁcient to induce the expression of the
target genes and may require additional convergent signals.
Since blinc2 is not induced by pro-inﬂammatory cytokines, the effect
of the lncRNA on NF-kB cannot reﬂect the release of IL-1b from
b-cells. Thus, the induction of blinc2 is likely to occur through a
different, yet to be identiﬁed, mechanism. This alternative pathway
may potentially synergize with the canonical cytokine-induced pathway
leading to a more drastic activation of NF-kB. Additional studies will be
needed to elucidate the mode of action of blinc2 and blinc3 and to
dissect the molecular events through which these lncRNAs can affect
the survival of b-cells. The lncRNAs Lethe and Nkila have been shown
to interact directly with components of the NF-kB pathway [50,51].
Future studies should determine whether this is also the case for
blinc2.
5. CONCLUSION
The discovery that mammalian genomes are extensively transcribed
and generate thousands of transcripts lacking protein-coding potential
has opened new perspectives in the study of the mechanisms regu-
lating the activity of b-cells and of the causes of their failure under
diabetic conditions. We have identiﬁed a large number of novel
lncRNAs many of which are modulated under obesity and T2D con-
ditions. At least two of them can affect the survival of b-cells and may
potentially contribute to glucolipotoxic-mediated b-cell loss and to the
manifestation and progression of T2D. The genome-wide data ob-
tained in this study will provide the basis for future investigations on
the involvement of other novel and potentially islet-speciﬁc lncRNAs in
b-cell dysfunction and T2D development. This may pave the way to the
identiﬁcation of new therapeutic targets for diabetes prevention and
treatment. Indeed, lncRNAs display a more restricted tissue distribution
than protein-coding genes [11,34], providing the ideal targets for
highly speciﬁc therapeutic interventions. Examples already exist wherepen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1415
Figure 8: Overexpression and downregulation of the lncRNAs blinc2 and blinc3 promotes apoptosis in MIN6 b cells. (A) MIN6 cells were transfected for 48 h with a control
plasmid (vector) or plasmids to induce the overexpression of the lncRNAs of interest. (B) The cells were transfected with a control gapmer or a gapmer targeting blinc3 to
knockdown this particular lncRNA. After 24 h of incubation, some of the cells were exposed to a mix of cytokines (0.1ng/ml IL-1b, 10ng/ml TNF-a and 30 ng/ml IFN-g) as a
positive control. The same experiments were repeated in dispersed mouse islet cells (C; D). The proportion of cells showing pyknotic nuclei was scored in at least 600 cells for
condition. Fold changes were calculated by dividing the results by the values obtained in the control condition. The data represent the means  SEM of 3e6 different experiments.
E. MIN6 cells were transfected for 48 h with a plasmid expressing GFP-tagged p65 (Rela). They were then exposed for 3 h to either a high dose of IL-1b (10ng/ml), Leptomycin B
(LMB) (22ng/ml) or a combination of the two. The number of cells displaying nuclear NF-kB localization were scored in at least 1500 cells for condition. Means  SEM of six
independent experiments. ANOVA, Tukey post-hoc test, *<0.05, **P < 0.01, ***p < 0.001.
Original Articlethe expression of these transcripts was manipulated in vivo in mice
[17,52].
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